BR112014027952A2 - anticorpos capazes de se ligar ao fator xi de coagulação e/ou à sua forma ativada fator xia e suas utilizações. - Google Patents

anticorpos capazes de se ligar ao fator xi de coagulação e/ou à sua forma ativada fator xia e suas utilizações.

Info

Publication number
BR112014027952A2
BR112014027952A2 BR112014027952A BR112014027952A BR112014027952A2 BR 112014027952 A2 BR112014027952 A2 BR 112014027952A2 BR 112014027952 A BR112014027952 A BR 112014027952A BR 112014027952 A BR112014027952 A BR 112014027952A BR 112014027952 A2 BR112014027952 A2 BR 112014027952A2
Authority
BR
Brazil
Prior art keywords
binding
antibodies capable
factor
activated
xia
Prior art date
Application number
BR112014027952A
Other languages
English (en)
Other versions
BR112014027952B1 (pt
Inventor
Wilmen Andreas
Buchmüller Anja
Itakura Asako
Gerdes Christoph
Tucker Erik
Dittmer Frank
Jöri\Ssen Hannah
Grudzinska-Goebel Joanna
Stra\Ssburger Julia
Schäfer Martina
Strerath Michael
Y Leung Philberta
Finnern Ricarda
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of BR112014027952A2 publication Critical patent/BR112014027952A2/pt
Publication of BR112014027952B1 publication Critical patent/BR112014027952B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

“anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi e/ou à sua forma ativada fator xia, seus usos, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor e hospedeiro” a presente invenção diz respeito a anticorpos capazes de se ligar ao fator xi de coagulação e/ou à sua forma ativada fator xia e a métodos para a sua utilização, em particular, métodos para a sua utilização como agentes para inibir a agregação de plaquetas e, devido a tal, inibir a formação de trombos.
BR112014027952-7A 2012-05-10 2013-05-08 Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor BR112014027952B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12167438.6 2012-05-10
EP12167438 2012-05-10
EP12181697 2012-08-24
EP12181697.9 2012-08-24
EP13150361.7 2013-01-07
EP13150361 2013-01-07
US201361817675P 2013-04-30 2013-04-30
US61/817,675 2013-04-30
PCT/EP2013/059618 WO2013167669A1 (en) 2012-05-10 2013-05-08 Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

Publications (2)

Publication Number Publication Date
BR112014027952A2 true BR112014027952A2 (pt) 2019-07-09
BR112014027952B1 BR112014027952B1 (pt) 2022-06-21

Family

ID=49550177

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014027952-7A BR112014027952B1 (pt) 2012-05-10 2013-05-08 Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor

Country Status (25)

Country Link
US (4) US9783614B2 (pt)
EP (2) EP2847228B1 (pt)
JP (2) JP6348900B2 (pt)
KR (1) KR102060376B1 (pt)
CN (1) CN104684932B (pt)
AR (1) AR091024A1 (pt)
AU (2) AU2013258043B2 (pt)
BR (1) BR112014027952B1 (pt)
CA (1) CA2872926C (pt)
DK (1) DK2847228T3 (pt)
ES (1) ES2698950T3 (pt)
HK (1) HK1207091A1 (pt)
HR (1) HRP20181680T1 (pt)
HU (1) HUE040580T2 (pt)
IL (1) IL235238B (pt)
LT (1) LT2847228T (pt)
MX (1) MX362454B (pt)
NZ (1) NZ701121A (pt)
PL (1) PL2847228T3 (pt)
RS (1) RS57889B1 (pt)
SG (2) SG11201406719UA (pt)
SI (1) SI2847228T1 (pt)
TW (2) TWI644925B (pt)
WO (1) WO2013167669A1 (pt)
ZA (1) ZA201407784B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566963T3 (es) 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
EP2373691B1 (en) 2008-12-18 2019-01-23 Oregon Health&Science University Anti-fxi antibodies and methods of use
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
IN2014CN02805A (pt) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
TWI586651B (zh) 2011-10-14 2017-06-11 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之經取代四氫異喹啉化合物
CN104684932B (zh) * 2012-05-10 2019-03-12 拜耳药业股份公司 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059203A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
NO2760821T3 (pt) 2014-01-31 2018-03-10
CN110845498B (zh) 2014-01-31 2023-02-17 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
PT3177642T (pt) 2014-08-07 2022-02-14 Novartis Ag Anticorpos semelhantes a angiopoietina 4 e métodos de uso
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
WO2016109774A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US11066481B2 (en) * 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
JOP20170013B1 (ar) 2016-01-22 2021-08-17 Merck Sharp & Dohme أجسام xi مضادة لعامل مضاد للتجلط
CA3018124A1 (en) * 2016-03-23 2017-09-28 Prothix Bv Monoclonal antibodies against the active site of factor xi and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
IL315266A (en) 2016-06-14 2024-10-01 Merck Sharp ַ& Dohme Llc Antibodies to coagulation factor XI
MX2019003077A (es) * 2016-09-20 2020-02-05 Bayer Pharma AG Anticuerpos novedosos contra el factor xi y sus usos.
US20200054719A1 (en) * 2016-11-02 2020-02-20 Erik Ian Tucker E-we thrombin analog and fibrinolytic combination
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
CN118320078A (zh) * 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
EP3570882B1 (en) * 2017-01-19 2021-11-17 Bayer Pharma Aktiengesellschaft Novel stable formulation for fxia antibodies
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
BR112020010016A2 (pt) 2017-11-22 2020-11-10 Novartis Ag agentes de ligação de reversão para anticorpos antifator xi/xia e usos dos mesmos
JP7149721B2 (ja) 2018-03-26 2022-10-07 株式会社Pfu 情報処理装置、文字認識エンジン最適化方法及びプログラム
PE20210462A1 (es) 2018-07-05 2021-03-08 Bayer Ag METODO PARA LA PRODUCCION DE GRANULOS LIOFILIZADOS QUE COMPRENDEN UN ANTICUERPO ANTI-FACTOR XIa (FXIa) DE LA COAGULACION
PE20211399A1 (es) * 2018-08-01 2021-07-27 Novo Nordisk As Anticuerpos procoagulantes mejorados
WO2020031514A1 (ja) 2018-08-07 2020-02-13 日本電信電話株式会社 光伝送システム及び伝送モード選択方法
CN114478782B (zh) * 2018-08-09 2024-04-02 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
AU2019344801A1 (en) * 2018-09-17 2021-05-20 Board Of Regents, The University Of Texas System Compositions and methods for treating bone injury
CA3117856A1 (en) 2018-10-31 2020-05-07 Bayer Aktiengesellschaft Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
CN113474373A (zh) * 2019-01-21 2021-10-01 阿罗诺拉股份有限公司 具有抗血栓形成和抗炎作用的新型抗因子xi人源化抗体及其用途
CN113474374A (zh) 2019-04-16 2021-10-01 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
CA3184718A1 (en) * 2020-07-02 2022-01-06 Lei Wang Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2024141099A1 (zh) * 2022-12-30 2024-07-04 甘李药业股份有限公司 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
DK0859841T3 (da) 1995-08-18 2002-09-09 Morphosys Ag Protein/(poly)peptidbiblioteker
US20030235587A1 (en) 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE59713007D1 (de) 1996-10-14 2009-06-25 Bayer Healthcare Ag Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
US20080219998A1 (en) 2001-12-07 2008-09-11 Andras Gruber Anti-Thrombotic Agents
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US20080138837A1 (en) 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7279513B2 (en) 2004-11-19 2007-10-09 Nalco Company Preparation of neutralized ethylene-acrylic acid polymer dispersions and use in printing media for improvement of digital toner adhesion
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
EA201201533A1 (ru) 2006-08-18 2014-11-28 Новартис Аг Prlr-специфическое антитело и его применения
CN101986783A (zh) 2007-04-23 2011-03-16 先灵公司 抗mdl-1抗体
WO2009046274A1 (en) 2007-10-03 2009-04-09 The University Of Vermont And State Agriculture College Methods of detection of factor xia and tissue factor
ES2566963T3 (es) * 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
HUE041556T2 (hu) * 2008-06-19 2019-05-28 Prothix Bv XI-es faktor elleni ellenanyagok alkalmazása vérrögképzõdés megelõzésére vagy kezelésére
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2373691B1 (en) * 2008-12-18 2019-01-23 Oregon Health&Science University Anti-fxi antibodies and methods of use
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
MA34330B1 (fr) 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble
EP2585055A1 (de) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
WO2012004258A1 (de) 2010-07-09 2012-01-12 Bayer Pharma Aktiengesellschaft Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
US9090610B2 (en) 2011-04-21 2015-07-28 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
KR20140074912A (ko) 2011-09-01 2014-06-18 에프. 호프만-라 로슈 아게 피롤로피라진 키나아제 억제제
BR112014005110A2 (pt) 2011-09-02 2017-04-18 Bayer Ip Gmbh pirimidinas aneladas substituídas e utilização das mesmas
CN104684932B (zh) 2012-05-10 2019-03-12 拜耳药业股份公司 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途

Also Published As

Publication number Publication date
US11046783B2 (en) 2021-06-29
US10040866B2 (en) 2018-08-07
US20190284300A1 (en) 2019-09-19
SG10201609322QA (en) 2017-01-27
US20180051093A1 (en) 2018-02-22
MX2014013568A (es) 2014-12-08
LT2847228T (lt) 2018-11-12
TW201400504A (zh) 2014-01-01
US10221247B2 (en) 2019-03-05
AR091024A1 (es) 2014-12-30
IL235238B (en) 2019-08-29
KR102060376B1 (ko) 2019-12-30
TW201811834A (zh) 2018-04-01
CA2872926A1 (en) 2013-11-14
PL2847228T3 (pl) 2019-03-29
AU2018200850A1 (en) 2018-02-22
IL235238A0 (en) 2014-12-31
US20150099298A1 (en) 2015-04-09
AU2018200850C1 (en) 2020-03-12
EP3404045A1 (en) 2018-11-21
MX362454B (es) 2019-01-18
ES2698950T3 (es) 2019-02-06
BR112014027952B1 (pt) 2022-06-21
AU2018200850B2 (en) 2019-09-19
DK2847228T3 (en) 2018-11-19
US9783614B2 (en) 2017-10-10
JP2015517305A (ja) 2015-06-22
ZA201407784B (en) 2019-01-30
US20180112009A1 (en) 2018-04-26
AU2013258043B2 (en) 2017-11-30
AU2013258043A1 (en) 2014-11-13
WO2013167669A1 (en) 2013-11-14
CA2872926C (en) 2022-07-05
HRP20181680T1 (hr) 2018-12-14
CN104684932B (zh) 2019-03-12
JP2018148920A (ja) 2018-09-27
TWI644925B (zh) 2018-12-21
KR20150008166A (ko) 2015-01-21
EP2847228A1 (en) 2015-03-18
NZ701121A (en) 2017-06-30
RS57889B1 (sr) 2019-01-31
TWI631140B (zh) 2018-08-01
JP6348900B2 (ja) 2018-06-27
HK1207091A1 (en) 2016-01-22
HUE040580T2 (hu) 2019-03-28
SI2847228T1 (sl) 2018-11-30
SG11201406719UA (en) 2014-11-27
CN104684932A (zh) 2015-06-03
EP2847228B1 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
BR112014027952A2 (pt) anticorpos capazes de se ligar ao fator xi de coagulação e/ou à sua forma ativada fator xia e suas utilizações.
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
CL2014002464A1 (es) Método para mejorar la eficacia de una transfusión de sangre que comprende la administración de una proteína sanguínea pegilada; oligómero de proteína sanguínea pegilada; proteína sanguínea pegilada; y composición que la comprende.
CY1121736T1 (el) Άλατα aramchol
BR112014019611A2 (pt) agentes de ligação mica
BR112013004581A2 (pt) imunoglobulinas de domínio variável dual e seus usos
BR112015003376A8 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
BR112016012860A2 (pt) Compostos de biarila úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia
AR089528A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
WO2013052943A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112015014372A2 (pt) inibidores de autotaxina
UA115657C2 (uk) Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
BR112014022000A2 (pt) compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
EA201690159A1 (ru) Способы и композиции для лечения рака
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
WO2016100347A3 (en) Small molecule inhibitors of egfr and pi3k
WO2014144763A3 (en) High affinity anti-gd2 antibodies
BR112017022255A2 (pt) anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica
BR112015014453A2 (pt) produtos de cuidado oral compreendendo cloreto de zinco tetrabásico e trimetilglicina
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
BR112013025294A2 (pt) moléculas de ligação biespecífica ligando a dll4 e ang2

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/05/2013, OBSERVADAS AS CONDICOES LEGAIS